Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer

H. Li, E. T. Shinohara, Q. Cai, H. Chen, R. Courtney, C. Cao, Z. Wang, M. Teng, W. Zheng, B. Lu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. Materials and methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer. Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38). Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.

Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalClinical Oncology
Volume18
Issue number4
Early online date15 Mar 2006
DOIs
Publication statusPublished - 1 May 2006
Externally publishedYes

Fingerprint

Plasminogen Activator Inhibitor 1
Prostatic Neoplasms
Genotype
Odds Ratio
Plasminogen
Paraffin
Single Nucleotide Polymorphism
Recurrence
DNA
Genes
Neoplasms

Cite this

Li, H. ; Shinohara, E. T. ; Cai, Q. ; Chen, H. ; Courtney, R. ; Cao, C. ; Wang, Z. ; Teng, M. ; Zheng, W. ; Lu, B. / Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer. In: Clinical Oncology. 2006 ; Vol. 18, No. 4. pp. 333-337.
@article{ed0f18cd7d074ade8bbd10a5afee9d2e,
title = "Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer",
abstract = "Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. Materials and methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer. Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95{\%} CI: 0.41-16.94, P = 0.30; OR = 2.19, 95{\%} CI: 0.38-12.49, P = 0.38). Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.",
keywords = "Aggressiveness, PAI-1, polymorphism, promoter, prostate cancer",
author = "H. Li and Shinohara, {E. T.} and Q. Cai and H. Chen and R. Courtney and C. Cao and Z. Wang and M. Teng and W. Zheng and B. Lu",
year = "2006",
month = "5",
day = "1",
doi = "10.1016/j.clon.2006.02.005",
language = "English",
volume = "18",
pages = "333--337",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Li, H, Shinohara, ET, Cai, Q, Chen, H, Courtney, R, Cao, C, Wang, Z, Teng, M, Zheng, W & Lu, B 2006, 'Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer', Clinical Oncology, vol. 18, no. 4, pp. 333-337. https://doi.org/10.1016/j.clon.2006.02.005

Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer. / Li, H.; Shinohara, E. T.; Cai, Q.; Chen, H.; Courtney, R.; Cao, C.; Wang, Z.; Teng, M.; Zheng, W.; Lu, B.

In: Clinical Oncology, Vol. 18, No. 4, 01.05.2006, p. 333-337.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer

AU - Li, H.

AU - Shinohara, E. T.

AU - Cai, Q.

AU - Chen, H.

AU - Courtney, R.

AU - Cao, C.

AU - Wang, Z.

AU - Teng, M.

AU - Zheng, W.

AU - Lu, B.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. Materials and methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer. Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38). Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.

AB - Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. Materials and methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer. Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38). Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.

KW - Aggressiveness

KW - PAI-1

KW - polymorphism

KW - promoter

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33645871610&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2006.02.005

DO - 10.1016/j.clon.2006.02.005

M3 - Article

VL - 18

SP - 333

EP - 337

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 4

ER -